• Skip to main content

DistilINFO LifeSciences

Weekly round up from Life Sciences Industry.

  • Publications
    • Home
    • DistilINFO HealthPlan
    • DistilINFO HospitalIT
    • DistilINFO IT
    • DistilINFO Retail
    • DistilINFO POPHealth
    • DistilINFO Ageing
    • DistilINFO Life Sciences
    • DistilINFO GovHealth
    • DistilINFO EHS
    • DistilINFO HealthIndia
    • Subscribe
    • Submit Article
    • Advertise
    • Newsletters

Genesis Biotechnology Group Acquires BioBlocks to Grow the Preclinical Chemistry Services Portfolio of Genesis Drug Discovery & Development (GD3)

Share:

October 13, 2021

Genesis Biotechnology Group® (GBG) and Contract Research Organization (CRO) arm Genesis Drug Discovery & Development™ (GD3) announced today that it has acquired BioBlocks. Founded in San Diego in 2002, BioBlocks provides medicinal chemistry drug discovery services and products to clients worldwide from initial lead discovery through the identification of development candidates.

This chemistry service portfolio addition will enable the GD3 member companies to expand their full-service drug research and discovery services to augment medicinal chemistry capabilities and accelerate screening, selection, and the advancement of industry partner’s drug candidates. With offices and laboratories in San Diego, California, and Budapest, Hungary, BioBlock’s skilled team of world-class chemists, with over 100 years of combined pharma and CRO experience, will work synergistically with GD3’s existing platform of chemistry services around uHTS, computational chemistry, and structural biology.

“We welcome the opportunity to become a member of the Genesis family of companies after 20 years of building an organization with strengths in medicinal chemistry expertise and collaborative drug discovery,” says Dr. Peter Pallai, CEO of BioBlocks. “By combining the complementary CRO capabilities of GD3 members and BioBlocks, we are creating a most comprehensive coverage of the drug discovery spectrum that will provide exceptional services to our pharma/biotech partners.”

“We constantly adapt our services to meet the needs of our industry partners,” says Dr. Eli Mordechai, CEO of GBG. “I believe that adding BioBlocks’ sector expertise and global reach is another way to differentiate our capabilities and significantly enhance our portfolio around medical chemistry to better serve our industry partners.”

Want to publish your own articles on DistilINFO Publications?

Send us an email, we will get in touch with you.

“While we continue to add complementary services to expand into new markets, we are also adding scale to increase market share with our existing services,” said Ben Bandaru, Ph.D., Director of Corporate Development for GBG. “The acquisition of BioBlocks is our first foray into establishing a base in the epicenter of European Biotech and Pharma, which seemed like our logical next step.”

Source: Biospace

Coffee with DistilINFO's Morning Updates...

Sign up for DistilINFO e-Newsletters.

Just a little bit more about you...
PROCEED
Choose Lists
BACK

Related Stories

  • Vitamin Shoppe -10% After Potential Higher Buyout Fizzles OutVitamin Shoppe -10% After Potential Higher Buyout Fizzles Out
  • Akoya Biosciences Acquires Phenoptics Portfolio from PerkinElmerAkoya Biosciences Acquires Phenoptics Portfolio from PerkinElmer
  • Qiagen Fully Acquires Neumodx Molecular, Inc., Rounding Out Portfolio of PCR-Based Diagnostic Automation SystemsQiagen Fully Acquires Neumodx Molecular, Inc., Rounding Out Portfolio of PCR-Based Diagnostic Automation Systems
  • Ibex Launches AI-powered Diagnostic System for Detecting Breast Cancer in PathologyIbex Launches AI-powered Diagnostic System for Detecting Breast Cancer in Pathology
  • Henry Schein closes North American Rescue acquisitionHenry Schein closes North American Rescue acquisition
  • Orchyd Launches Period Tracker with Smart WalletOrchyd Launches Period Tracker with Smart Wallet
  • Grunenthal Agrees US$ 922 m Deal With AstraZeneca for Nexium and VimovoGrunenthal Agrees US$ 922 m Deal With AstraZeneca for Nexium and Vimovo
  • Working towards a future where people can live (and die) healthyWorking towards a future where people can live (and die) healthy

Trending This Week

Sorry. No data so far.

About Us

DistilINFO is media company that publishes Industry news, views and Interviews. We distil the information for you – saving time and keeping you up to date on your interest areas.

More About Us

Follow Us


Useful Links

  • Subscribe
  • Contact
  • Advertise
  • Privacy Policy
  • Terms of Service
  • Feedback

All Publications

  • DistilINFO HealthPlan Advisory
  • DistilINFO HospitalIT Advisory
  • DistilINFO IT Advisory
  • DistilINFO Retail Advisory
  • DistilINFO POPHealth Advisory
  • DistilINFO Ageing Advisory
  • DistilINFO Life Sciences Advisory
  • DistilINFO GovHealth Advisory
  • DistilINFO EHS Advisory
  • DistilINFO HealthIndia Advisory

© DistilINFO Publications